[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts",
    "summary": "Vertex Pharmaceuticals (VRTX) reached $452.16 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=c639a7e21ffa39f5a15a878b0af2e814accfc38a8c4b5cb66d283e5c32f50a7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751407205,
      "headline": "Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts",
      "id": 135702094,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) reached $452.16 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=c639a7e21ffa39f5a15a878b0af2e814accfc38a8c4b5cb66d283e5c32f50a7e"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=78cd5e097419d50a9ab1687d954bcbf51d9f8dc6afb005d9950acfc2336783a4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751387820,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
      "id": 135732754,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=78cd5e097419d50a9ab1687d954bcbf51d9f8dc6afb005d9950acfc2336783a4"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Announces European Commission Approval of ALYFTREK, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis",
    "summary": "Vertex Pharmaceuticals announced that the European Commission has granted approval for ALYFTREK in combination with ivacaftor on ppFEV1 and superior at reducing sweat chloride, demonstrating greater...",
    "url": "https://finnhub.io/api/news?id=38cf4bc65ffeaf183f38dd801b4680a7637892fa34d31d971f3c2da919c8862c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751377915,
      "headline": "Vertex Pharmaceuticals Announces European Commission Approval of ALYFTREK, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis",
      "id": 135696010,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "Vertex Pharmaceuticals announced that the European Commission has granted approval for ALYFTREK in combination with ivacaftor on ppFEV1 and superior at reducing sweat chloride, demonstrating greater...",
      "url": "https://finnhub.io/api/news?id=38cf4bc65ffeaf183f38dd801b4680a7637892fa34d31d971f3c2da919c8862c"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Announces European Commission Approval of ALYFTREK速, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis",
    "summary": "LONDON, July 01, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK速 (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.",
    "url": "https://finnhub.io/api/news?id=cc6340c58ca9079e6a7f4daf62e3ccb474a8433c8c25ecedf889dae680ef3c39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751369640,
      "headline": "Vertex Announces European Commission Approval of ALYFTREK速, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis",
      "id": 135694270,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "LONDON, July 01, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK速 (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.",
      "url": "https://finnhub.io/api/news?id=cc6340c58ca9079e6a7f4daf62e3ccb474a8433c8c25ecedf889dae680ef3c39"
    }
  },
  {
    "ts": null,
    "headline": "EU approves Vertex's next-generation cystic fibrosis drug",
    "summary": "Vertex said on Tuesday thatits next-generation drug gained European Commission approval fortreating cystic fibrosis, a rare and progressive geneticdisease. The approval expands the...",
    "url": "https://finnhub.io/api/news?id=fcb73bcb53ace30917dfd988bdb5cbe446a051e78bfa2f1a11c425286cdb9f20",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751357056,
      "headline": "EU approves Vertex's next-generation cystic fibrosis drug",
      "id": 135688281,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "Vertex said on Tuesday thatits next-generation drug gained European Commission approval fortreating cystic fibrosis, a rare and progressive geneticdisease. The approval expands the...",
      "url": "https://finnhub.io/api/news?id=fcb73bcb53ace30917dfd988bdb5cbe446a051e78bfa2f1a11c425286cdb9f20"
    }
  },
  {
    "ts": null,
    "headline": "Vertex's next-generation cystic fibrosis drug gets EU approval",
    "summary": "Vertex said on Tuesday that its next-generation drug, Alyftrek, gained European Commission approval for the treatment of cystic fibrosis. CF is an inherited disorder resulting from the...",
    "url": "https://finnhub.io/api/news?id=f113811330ebb6728eeb864656552b0ecef0d17f76adab3d4d4f0111f0bcb722",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751356031,
      "headline": "Vertex's next-generation cystic fibrosis drug gets EU approval",
      "id": 135688146,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "Vertex said on Tuesday that its next-generation drug, Alyftrek, gained European Commission approval for the treatment of cystic fibrosis. CF is an inherited disorder resulting from the...",
      "url": "https://finnhub.io/api/news?id=f113811330ebb6728eeb864656552b0ecef0d17f76adab3d4d4f0111f0bcb722"
    }
  }
]